Highly motivated, innovative and collaborative scientist with 25 years of experience in virology and immunology, with broad experience in drug discovery and development. This includes:- Extensive experience developing research strategies, as well as leading discovery and supporting development of direct-acting antivirals and immunomodulatory agents. - More than 20 years of management and leadership experience in small biotech (Anadys), medium biopharma (Gilead) and large pharma (Roche); currently lead team of 40+ scientists.- Extensive virology experience, including hepatitis viruses (HBV, HCV, HDV), respiratory viruses (e.g., RSV, SARS-CoV-2) and herpesviruses (e.g., CMV, HSV).- Broad immunology experience, including discovery and development of diverse immune modulators (e.g., TLR agonists, checkpoint inhibitors, therapeutic vaccines).- Experience with discovering and developing novel agents with different modalities (small molecules, antibodies and other biologics, viral vector vaccines).- Experience supporting agents from early discovery through Phase 2 and various regulatory filings (IND, CTA, SCOTT, investigator brochures, product labels).- Extensive experience interacting with functions across biopharmaceutical organizations (e.g., research, clinical development, corporate development, commercial, regulatory, med affairs).- Extensive experience working with diverse external partners (CRO, biotech and pharma organizations, as well as academic groups). - Experience with in-licensing, acquisition and out-licensing deals.Specialties: virology; antivirals; immunology; innate immunity; immunotherapies; viral hepatitis; HBV; HCV; HDV; herpesviruses; CMV; HSV; RSV; COVID; SARS-CoV-2; pandemic preparedness; translational medicine; molecular biology; cell biology